Stockscreener 앱 받기
30.44
11.23%
-3.85
시간 외 거래:
29.22
-1.22
-4.01%
Uniqure N V 주식(QURE)의 최신 뉴스
UniQure Is Latest Gene Therapy Sponsor Surprised By US FDA Reversal - Citeline News & Insights
Chardan Capital Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price - MarketBeat
Top Small Cap Stocks To Follow TodayNovember 3rd - MarketBeat
uniQure N.V. Securities Lawsuit Investigation - Claim Depot
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy - Benzinga
uniQure (QURE) Sees Analyst Price Target Lowered by RBC Capital | QURE Stock News - GuruFocus
uniQure (NASDAQ:QURE) Shares Gap DownHere's Why - MarketBeat
uniQure (QURE) Analyst Rating Update: Goldman Sachs Lowers Price Target | QURE Stock News - GuruFocus
uniQure (QURE) Shares Drop Over 15% Amid Market Shifts - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Cuts Target Price to $38 - 富途牛牛
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - FinancialContent
UniQure: Controversy Abounds As Stock Price Halves On FDA News (NASDAQ:QURE) - Seeking Alpha
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $70 - 富途牛牛
Chardan Cuts Price Target on uniQure to $53 From $76, Keeps Buy Rating - MarketScreener
RBC Cuts Price Target on uniQure to $45 From $65, Keeps Outperform, Speculative Risk - MarketScreener
William Blair Downgrades uniQure N.V to Market Perform From Outperform - MarketScreener
uniQure (QURE) Downgraded by William Blair to Market Perform | Q - GuruFocus
uniQure stock price target lowered to $70 at H.C. Wainwright on FDA setback - Investing.com Nigeria
uniQure (QURE) Price Target Lowered by HC Wainwright & Co. | QUR - GuruFocus
HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
uniQure (QURE) Downgraded by William Blair Amid Uncertainty Over AMT-130 - GuruFocus
uniQure Stock Tumbled 55% Today: What’s The FDA Angle? - MSN
William Blair Downgrades UniQure NV(QURE.US) to Hold Rating - 富途牛牛
UniQure Insiders Who Sold Avert US$2.1b Market Cap Dip - 富途牛牛
Predicting uniQure N.V. trend using moving averagesChart Signals & Real-Time Chart Pattern Alerts - newser.com
Volatility clustering patterns for uniQure N.V.Dip Buying & Long-Term Capital Growth Strategies - newser.com
Can uniQure N.V. stock hit analyst price targetsMarket Volume Summary & Community Consensus Stock Picks - newser.com
Risk adjusted return profile for uniQure N.V. analyzedJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
What catalysts could drive uniQure N.V. stock higherTrade Analysis Summary & AI Optimized Trade Strategies - newser.com
Is uniQure N.V. stock a bargain at current levelsJuly 2025 WrapUp & Precise Entry and Exit Recommendations - newser.com
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data - CGTLive®
QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors Should Contact the Firm to Potentially Recover Losses - Supply Chain Digital Magazine
FDA’s rebuff of uniQure raises uncertainty over external control standards - BioCentury
How FDA’s Revised Stance on AMT-130 Data Has Changed uniQure’s (QURE) Investment Story - simplywall.st
uniQure (QURE) Maintains Buy Rating as Chardan Capital Lowers Pr - GuruFocus
UniQure Reeling As FDA Reverses Stance On Accelerated Approval For AMT-130 - Citeline News & Insights
UniQure Shares Dive After ‘Surprising’ Pivot by FDA on Drug Data - Bloomberg
QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors ... - Bluefield Daily Telegraph
QURE Investor ALERT: Block & Leviton Investigating uniQure - GlobeNewswire
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC - GlobeNewswire
Why UniQure Stock Is Plunging TodayuniQure (NASDAQ:QURE) - Benzinga
uniQure N.V. (QURE) Stock: Plunges 57% After Unexpected FDA Setback on AMT-130 - CoinCentral
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - The AI Journal
uniQure (QURE) Shares Plunge Over 50% - GuruFocus
uniQure (QURE) Faces Setback with FDA on AMT-130 BLA Submission - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $110 - 富途牛牛
UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy - Reuters
UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enoughhere's what i - The Economic Times
uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results - MSN
uniQure stock falls after FDA feedback on gene therapy application - Seeking Alpha
uniQure (QURE) Faces FDA Reversal on AMT-130 Phase 1/2 Data - GuruFocus
Uniqure stock plunges after FDA rejects company’s clinical data for Huntington's therapy - Proactive financial news
uniQure (QURE) Shares Plummet Over 57% - GuruFocus
UniQure (QURE) Stock: Biotech Plunges 67% After FDA Reverses Position on Gene Therapy Data - parameter.io
UniQure Shares Fall Sharply as Trading Resumes After Volatility Halt - MarketScreener
uniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – QURE - The Globe and Mail
UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. -- Barrons.com - 富途牛牛
Top Premarket Decliners - 富途牛牛
How analysts rate uniQure N.V. stock today2025 Analyst Calls & Real-Time Buy Zone Alerts - newser.com
uniQure Shares Collapse 75% After FDA Reverses Position on Huntington’s Therapy - MSN
UniQure’s FDA submission for its Huntington’s disease therapy thrown into question - statnews.com
UniQure Shares Fall Pre-Bell After FDA Raises Questions on Huntington's Disease Therapy Data - MarketScreener
1.45%
0.86%
자본화:
|
볼륨(24시간):